Subdivision of intermediate suspicion, the 2021 K-TIRADS, and category III, indeterminate cytology, the 2017 TBSRTC, 2nd edition, in thyroidology: let bygones be bygones?

The Potential Role of Virus Infection in the Progression of Thyroid Cancer

“…Undoubtedly, indeterminate cytology was highlighted as a subdivision needing urgently addressed [7][8][9]. Subdivision of intermediate suspicion is crucial for effective FNA and the size of the fine needle, which could decrease the implied ROM [10,11].…”

Is the neutrophil-to-lymphocyte "ratio"nale from head and neck to thyroidology for thyroidologists?: promise or passé?

“…Moreover, he proposed that N/L can be utilized as a biomarker beyond fine needle aspiration cytology. Thereto, he highlighted N/L as being proven in distinguishing between benign and malignant nodules in patients 1 with suspicious thyroid nodules 1,[5][6][7][8][9][10][11][12][13][14][15][16][17] . Nevertheless, at least a minimal debate is still ongoing on an accurate decision on N/L whether it is a biomarker in discrimination of malignity or not.…”

The 2023 Bethesda system for reporting thyroid cytopathology: novi sub sole, subdivision is no more debatable, in thyroidology

“…Of note, we postulated in this publication in the 67th volume of Rev Assoc Med Bras that the so-called subdivision demand and so kind of reality in category III, TBSRTC, 2nd edition as (i) Category IIIA: AUS/FLUS without nuclear atypia (AUS/FLUS wo NA) and (ii) Category IIIB: AUS/FLUS with nuclear atypia (AUS/FLUS w NA) 22 , which is very similar to that of Ali et al 14 . Finally, we have also currently recommended working with subdivisions instead of insisting on a monolithic category III to be able to resolve the issue of the ongoing debate on indeterminate cytology in our epub ahead of the print article in Ultrasonography with a submission date of June 08, 2023 23 .…”